Current stock page

Financial Data

ABBV Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareDrug Manufacturers - GeneralScore data as of Oct 21, 2026

ABBVAbbVie Inc.

Healthcare / Drug Manufacturers - General

Low Priority

Above Peers

NeutralEdge 6/10
$284.80−$4.28 (−1.48%)

Latest quote

  • Momentum
    82
  • Value
    36
  • Quality
    60
  • Risk resilience
    44
  • Sentiment
    86
algovestiq.comScore data as of Oct 21, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
3
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Oct 22, 2026.

Income statement
3 periods
Metric2026-06-302026-03-312025-12-31
Revenue$16.99B$15B$16.62B
Gross Profit$12.7B$10.78B$12.07B
Operating Income$6.43B$4.73B$5.81B
Net Income$3.61B$699M$1.82B
EPS$2.04$0.39$1.02
Cash flow statement
3 periods
Metric2026-06-302026-03-312025-12-31
Operating Cash Flow$3.44B$3.83B$5.22B
Capital Expenditure$265M-$265M-$329M
Free Cash Flow$3.7B$3.56B$4.89B
Net Cash Provided By Operating Activities$3.44B$3.83B$5.22B
Balance sheet
3 periods
Metric2026-06-302026-03-312025-12-31
Total Assets$135.13B$136.46B$5.46B
Total Debt$70.03B$72.38B$438.83B
Cash And Cash Equivalents———
Total Liabilities$141B$143.08B$26.29B
Total Stockholders Equity-$5.87B-$6.61B-$20.84B
Key financial metrics
3 periods
Metric2026-06-302026-03-312025-12-31
P/E ratio30.84139.4256
P/B ratio-75.09-57.96-123.96
P/S ratio26.2325.7224.39
Debt To Equity-11.93-10.95-21.06
Free Cash Flow Yield0.83%0.92%1.21%
Financial ratios
3 periods
Metric2026-06-302026-03-312025-12-31
P/E ratio30.84139.4256
P/B ratio-75.09-57.96-123.96
P/S ratio26.2325.7224.39
Return On Equity-60.88%-10.50%-55.54%
Debt To Equity-11.93-10.95-21.06

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe73.25x
Pb-77.58x
Gross Margin71.48%
Operating Margin29.32%
ROE-136.50%
ROIC13.46%
Debt To Equity-11.93
FCF Yield4.28%

As of Oct 21, 2026

Technical indicators
MetricValue
Close$284.80
Volume4.39M
RSI (14)73.65
MACD6.64
MACD signal5.41
MACD histogram1.24
ADX (14)34.76
SMA (50)$264.70
SMA (200)$234.84
ATR (14)$6.51
Historical volatility (annualized)21.98%
Volume (20-day average)5.06M

As of Oct 21, 2026

Risk measures
MetricValue
Resilience score44/100
Beta0.28
Annual volatility25.89%
Max Drawdown-16.46%
Sharpe Ratio0.77
VaR (95%, 1-day)-2.41%

As of Oct 21, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ABBV Financial Data FAQ

What is AbbVie Inc.'s revenue?

AbbVie Inc.'s revenue is one of the core financial data points for ABBV. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is AbbVie Inc.'s revenue growing?

Revenue growth shows whether AbbVie Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ABBV's EPS?

ABBV's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is AbbVie Inc.'s net income?

AbbVie Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does AbbVie Inc. generate?

Free cash flow shows how much cash AbbVie Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does AbbVie Inc. have?

Cash and debt help frame ABBV's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.